количество зарегистрированных пользователей: 66696

Rumedo Медицинский образовательный портал

МЕДИЦИНСКИЙ ОБРАЗОВАТЕЛЬНЫЙ ПОРТАЛ

Академия инновационного образования

Клиническая задача и разбор №13. Пациентка с сахарным диабетом 2-го типа и факторами сердечно-сосудистого риска

Вернуться к материалу

По категориям

По специальностям

  • Зарубежные материалы

    ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

    Дата публикации 22.10.2020
    Автор: : Lars Ryde´n* (ESC Chairperson) (Sweden), Peter J. Grant* (EASD Chairperson) (UK), Stefan D. Anker (Germany), Christian Berne (Sweden), Francesco Cosentino (Italy), Nicolas Danchin (France), Christi Deaton (UK), Javier Escaned (Spain), Hans-Peter Hammes (Germany), Heikki Huikuri (Finland), Michel Marre (France), Nikolaus Marx (Germany), Linda Mellbin (Sweden), Jan Ostergren (Sweden), Carlo Patrono (Italy), Petar Seferovic (Serbia), Miguel Sousa Uva (Portugal), Marja-Riita Taskinen (Finland), Michal Tendera (Poland), Jaakko Tuomilehto (Finland), Paul Valensi (France), Jose Luis Zamorano (Spain)

    The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology(ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD).

    Подробнее

    426

  • Зарубежные материалы

    Chronic Kidney Disease and the Risk of End-Stage Renal Disease versus Death

    Дата публикации 22.10.2020
    Автор: Lorien S. Dalrymple, MD, MPH1, Ronit Katz, DPhil 2, Bryan Kestenbaum, MD, MS 3, Michael G. Shlipak, MD, MPH4,5, Mark J. Sarnak, MD, MS 6, Catherine Stehman-Breen, MD, MS 7, Stephen Seliger, MD, MS 8, David Siscovick, MD, MPH3,9, Anne B. Newman, MD, MPH10,11, and Linda Fried, MD, MPH10,11,12

    In the United States, approximately one in three adults aged 65 years and older has chronic kidney disease (CKD), defined as an eGFR ...

    Подробнее

    556

  • Зарубежные материалы

    Structured lifestyle education for people with schizophrenia, schizoaffective disorder and first-episode psychosis (STEPWISE): randomised controlled trial

    Дата публикации 22.10.2020
    Автор: Richard I. G. Holt, Rebecca Gossage-Worrall, Daniel Hind, Michael J. Bradburn, Paul McCrone, Tiyi Morris, Charlotte Edwardson, Katharine Barnard, Marian E. Carey, Melanie J. Davies, Chris M. Dickens, Yvonne Doherty, Angela Etherington, Paul French, Fiona Gaughran, Kathryn E. Greenwood, Sridevi Kalidindi, Kamlesh Khunti, Richard Laugharne, John Pendlebury, Shanaya Rathod, David Saxon, David Shiers, Najma Siddiqi, Elizabeth A. Swaby, Glenn Waller and Stephen Wright on behalf of the STEPWISE Research Group*

    People with schizophrenia die 10–20 years earlier than the general population, with approximately 75% of deaths resulting from physical illness.1 The twofold increased prevalence of overweight and obesity contributes to this excess mortality.2 Some, but not all, studies suggest that dietary

    Подробнее

    426

  • Зарубежные материалы

    Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and theEuropeanAssociation for the Study of Diabetes (EASD)

    Дата публикации 22.10.2020
    Автор: Melanie J. Davies,1,2 David A. D’Alessio,3 Judith Fradkin,4 Walter N. Kernan,5 Chantal Mathieu,6 Geltrude Mingrone,7,8 Peter Rossing,9,10 Apostolos Tsapas,11 Deborah J. Wexler,12,13 and John B. Buse14

    The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the prior position statements, published in 2012 and 2015, on the management of type 2 diabetes in adults. A systematic evaluation of the literature since 2014 informed new recommendations. These include additional focus on lifestyle management and diabetes self-management education ...

    Подробнее

    540

  • Зарубежные материалы

    9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetesd2019

    Дата публикации 22.10.2020
    Автор: American Diabetes Association

    The American Diabetes Association (ADA) “Standards of Medical Care in Diabetes” includes ADA’s current clinical practice recommendations and is intended to provide the components of diabetes care, general treatment goals and guidelines, and tools to evaluate quality of care.

    Подробнее

    827

  • Зарубежные материалы

    Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientifc evidence from across the world in 2007–2017

    Дата публикации 22.10.2020
    Автор: Thomas R. Einarson, Annabel Acs, Craig Ludwig and Ulrik H. Panton

    Te International Diabetes Federation (IDF) estimates that worldwide, 415 million people have diabetes, 91% of whom have type 2 diabetes mellitus (T2DM). People with diabetes comprise 8.8% of the world’s population, and IDF predicts that the number of cases of diabetes will rise to 642 million by 2040

    Подробнее

    634

  • Зарубежные материалы

    Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Jennifer B. Green, M.D., M. Angelyn Bethel, M.D., Paul W. Armstrong, M.D., John B. Buse, M.D., Ph.D., Samuel S. Engel, M.D., Jyotsna Garg, M.S., Robert Josse, M.B., B.S., Keith D. Kaufman, M.D., Joerg Koglin, M.D., Scott Korn, M.D., John M. Lachin, Sc.D., Darren K. McGuire, M.D., M.H.Sc., Michael J. Pencina, Ph.D., Eberhard Standl, M.D., Ph.D., Peter P. Stein, M.D., Shailaja Suryawanshi, Ph.D., Frans Van de Werf, M.D., Ph.D., Eric D. Peterson, M.D., M.P.H., and Rury R. Holman, M.B., Ch.B., for the TECOS Study Group*

    Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease.

    Подробнее

    406

  • Зарубежные материалы

    Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Rury R. Holman, F.Med.Sci., M. Angelyn Bethel, M.D., Robert J. Mentz, M.D., Vivian P. Thompson, M.P.H., Yuliya Lokhnygina, Ph.D., John B. Buse, M.D., Ph.D., Juliana C. Chan, M.D., Jasmine Choi, M.S., Stephanie M. Gustavson, Ph.D., Nayyar Iqbal, M.D., Aldo P. Maggioni, M.D., Steven P. Marso, M.D., Peter Öhman, M.D., Ph.D., Neha J. Pagidipati, M.D., M.P.H., Neil Poulter, F.Med.Sci., Ambady Ramachandran, M.D., Bernard Zinman, M.D., and Adrian F. Hernandez, M.D., M.H.S., for the EXSCEL Study Group*

    The cardiovascular effects of adding once-weekly treatment with exenatide to usual care in patients with type 2 diabetes are unknown.

    Подробнее

    425

  • Зарубежные материалы

    Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

    Дата публикации 22.10.2020
    Автор: SILVIO E. INZUCCHI, MD1 RICHARD M. BERGENSTAL, MD2 JOHN B. BUSE, MD, PHD3 MICHAELA DIAMANT, MD, PHD4 ELE FERRANNINI, MD5 MICHAEL NAUCK, MD6 ANNE L. PETERS, MD7 APOSTOLOS TSAPAS, MD, PHD8 RICHARD WENDER, MD9 DAVID R. MATTHEWS, MD, DPHIL10,

    Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

    Подробнее

    563

  • Зарубежные материалы

    Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

    Дата публикации 22.10.2020
    Автор: Steven E. Kahn, M.B., Ch.B., Steven M. Haffner, M.D., Mark A. Heise, Ph.D., William H. Herman, M.D., M.P.H., Rury R. Holman, F.R.C.P., Nigel P. Jones, M.A., Barbara G. Kravitz, M.S., John M. Lachin, Sc.D., M. Colleen O’Neill, B.Sc., Bernard Zinman, M.D., F.R.C.P.C., and Giancarlo Viberti, M.D., F.R.C.P., for the ADOPT Study Group *

    The efficacy of thiazolidinediones, as compared with other oral glucose-lowering medications, in maintaining long-term glycemic control in type 2 diabetes is not known.

    Подробнее

    503

  • Зарубежные материалы

    Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus

    Дата публикации 22.10.2020
    Автор: Eri T. Kato, MD, MPH, PhD et al

    In DECLARE-TIMI 58 (Dapagliflozin Effect on Cardiovascular Events–Thrombolysis in Myocardial Infarction 58), the sodium-glucose cotransporter 2 inhibitor dapagliflozin reduced the composite end point of cardiovascular death/hospitalization for heart failure (HHF) in a broad population of patients with type 2 diabetes mellitus. However, the impact of baseline left ventricular ejection fraction (EF) ...

    Подробнее

    562

  • Зарубежные материалы

    Kidney Disease as a Risk Factor for Development of Cardiovascular Disease

    Дата публикации 22.10.2020
    Автор: Mark J. Sarnak, MD, Cochair; Andrew S. Levey, MD, Cochair; Anton C. Schoolwerth, MD, Cochair; Josef Coresh, MD, PhD; Bruce Culleton, MD; L. Lee Hamm, MD; Peter A. McCullough, MD, MPH; Bertram L. Kasiske, MD; Ellie Kelepouris, MD; Michael J. Klag, MD, MPH; Patrick Parfrey, MD; Marc Pfeffer, MD, PhD; Leopoldo Raij, MD; David J. Spinosa, MD; Peter W. Wilson, MD

    A Statement From the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention

    Подробнее

    659

  • Зарубежные материалы

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (HHS Public Access)

    Дата публикации 22.10.2020
    Автор: Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D. for the LEADER Steering Committee on behalf of the LEADER Trial Investigators

    The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

    Подробнее

    670

  • Зарубежные материалы

    Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (The new england journal of medicine)

    Дата публикации 22.10.2020
    Автор: Steven P. Marso, M.D., Gilbert H. Daniels, M.D., Kirstine Brown-Frandsen, M.D., Peter Kristensen, M.D., E.M.B.A., Johannes F.E. Mann, M.D., Michael A. Nauck, M.D., Steven E. Nissen, M.D., Stuart Pocock, Ph.D., Neil R. Poulter, F.Med.Sci., Lasse S. Ravn, M.D., Ph.D., William M. Steinberg, M.D., Mette Stockner, M.D., Bernard Zinman, M.D., Richard M. Bergenstal, M.D., and John B. Buse, M.D., Ph.D., for the LEADER Steering Committee on behalf of the LEADER Trial Investigators

    The cardiovascular effect of liraglutide, a glucagon-like peptide 1 analogue, when added to standard care in patients with type 2 diabetes, remains unknown.

    Подробнее

    440

  • Зарубежные материалы

    Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

    Дата публикации 22.10.2020
    Автор: Steven P. Marso, M.D., Stephen C. Bain, M.D., Agostino Consoli, M.D., Freddy G. Eliaschewitz, M.D., Esteban Jódar, M.D., Lawrence A. Leiter, M.D., Ildiko Lingvay, M.D., M.P.H., M.S.C.S., Julio Rosenstock, M.D., Jochen Seufert, M.D., Ph.D., Mark L. Warren, M.D., Vincent Woo, M.D., Oluf Hansen, M.Sc., Anders G. Holst, M.D., Ph.D., Jonas Pettersson, M.D., Ph.D., and Tina Vilsbøll, M.D., D.M.Sc., for the SUSTAIN-6 Investigators

    Regulatory guidance specifies the need to establish cardiovascular safety of new diabetes therapies in patients with type 2 diabetes in order to rule out excess cardiovascular risk. The cardiovascular effects of semaglutide, a glucagon-like peptide 1 analogue with an extended half-life of approximately 1 week, in type 2 diabetes are unknown.

    Подробнее

    542